Defense Personnel Support Center, 2800 S 20Th Street, Phila PA 19101-8419

65 -- TREATMENT OF VAGINAL CANDIDIASIS SOL SP0200-95-1012 DUE 103095 POC Contact: Andrea J. Ries, pharm. D. Drug information special ist amedd pharmacoeconomic Center Attn: Afzg-dl /Bldg 4197 Ft. SAM Houston, TX 78234-5000 This is a Market survey for the treatement of vaginalcandidiasis. See remarks: The pharmacoeconomic Center (PEC) is reviewing information to develop analytic methodologies to evaluate the treatment of vulvovaginal candidiasis in the Military Health service system. Manufacturers of products used for the treatment of vulvovaginalcandidiasis are invited to present pharmacoeconomic infomation to the PEC. This infomation will assist in developing an evaluation Model for product selection for the Tri-service formulary. Types of information being reviewed include head to head effectiveness studies of competing therapies, pharmacoeconomic and/or quality of life studies ofvulvovaginal candidiasis, pharmacoepidemiologicalinformation or studies of vulvovaginal candidiasisand any unpublished data relevant to the treatment of vulvovaginal candidiasis. Up to one hour is the preferred length of a presentation; not more than two hours will be allotted for a presentation. Each manufacturer will be limited to one presentation on vulvovaginal candidiasis. For further information, contact Andrea J. Ries, pharm. D. Pharmacoeconomiccenter, Attn: Afzg-dl, Bldg. 4197, 2107 17th St., Ft. San Houston, TX 7823-5036. The Contracting offficer on this Market survey is Francis E. Tallent, Contracting Officer DPSC-mgab-pea. All responsible sources may submit offer which DPSC shall consider(0275)

Loren Data Corp. http://www.ld.com (SYN# 0253 19951003\65-0002.SOL)